6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
about
Human Cancer Immunotherapy with PD-1/PD-L1 BlockadeT cell activation and differentiation is modulated by a CD6 domain 1 antibody ItolizumabCD6 as a therapeutic target in autoimmune diseases: successes and challenges.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.Worldwide experience with biosimilar development.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.Biomarkers in diabetic retinopathy and the therapeutic implications.Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasisItolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.Tackling non-muscle invasive bladder cancer in the clinic.Biosimilar, biobetter and next generation therapeutic antibodiesMabs's communication networks.The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).Antibody-drug conjugates: present and future.Update on immune checkpoint inhibitors in lung cancer
P2860
Q26786108-6180FDA8-12D0-4176-92FC-EB9E8A06DA7DQ33865748-B4E19CD5-0CA1-4A6F-B248-5777EF278CA0Q34337963-F65882DA-D611-4D43-8645-BD4B882E93A3Q34809019-59283663-72C6-4C95-91CD-C17927E43DCBQ34974791-9E04B211-0CF5-4A83-89A3-EE5BE1F3EC66Q35992488-887D907E-3AC0-473B-A383-77BBBAB904C7Q37158481-B643907B-4ED4-4260-9EFE-9C53C8E2BA52Q37702430-11C0DD10-4798-456A-BB75-BEFC9D018620Q38082845-64AACDF9-53A7-43B5-8996-2C5790010354Q38169142-F6FA9BF3-40E9-4C60-8589-F9B8F590E283Q38461733-B0F1B0B6-B77D-4BCC-9601-7D2C0805A573Q39033726-FA722A94-4AE5-46B5-A534-38E305FFBD32Q39209020-802BC4A4-2AA8-4662-A616-66ABB227D369Q42732007-91BB614A-5F67-4C4F-AA76-69BACC1B043BQ43183813-2AD92F98-4D91-4208-BED7-53E9DF3CD133Q48265755-D01CDBC9-1B28-4708-A83C-56B29A30F4A7Q51075376-AC0A1DFF-912C-492D-90F0-6B186CB5FF3CQ51317043-82BE1080-E79E-49F0-8EED-5BB1F995C7CCQ56897146-DFCC5C90-68EE-494F-B288-65747990F249
P2860
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@en
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@nl
type
label
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@en
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@nl
prefLabel
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@en
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@nl
P2860
P356
P1476
6th Annual European Antibody C ...... 1, 2010, Geneva, Switzerland.
@en
P2093
Alain Beck
Thierry Wurch
P2860
P304
P356
10.4161/MABS.3.2.14788
P577
2011-03-01T00:00:00Z